Goldman Sachs analyst Salveen Richter downgraded bluebird bio (NASDAQ: BLUE) from Neutral to Sell with a price target of $10.00 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Downgrades Hot Comments Hot Downgrades

bluebird bio (BLUE) PT Lowered to $16 at Wells FargoNovember 8, 2021 6:33 AM bluebird bio (BLUE) PT Lowered to $14 at RBC CapitalNovember 8, 2021 6:28 AM bluebird bio (BLUE) PT Lowered to $11 at WedbushNovember 8, 2021 6:20 AM Morgan Stanley Downgrades bluebird bio (BLUE) to Underweight, 'commercialization will remain challenging'November 8, 2021 5:11 AM bluebird bio (BLUE) PT Lowered to $13 at BarclaysNovember 8, 2021 4:08 AM bluebird bio (BLUE) Misses Q3 EPS by 56cNovember 5, 2021 7:17 AM Form 10-Q bluebird bio, Inc. For: Sep 30November 5, 2021 7:15 AM Form 8-K bluebird bio, Inc. For: Nov 05November 5, 2021 7:09 AM bluebird bio Reports Third Quarter Financial Results and Recent Operational ProgressNovember 5, 2021 7:05 AM bluebird bio and Federal Realty to Establish Biotech Footprint at Assembly Row  November 5, 2021 6:58 AM bluebird bio to Present New Gene Therapy Data at the 63rd American Society of Hematology (ASH) Annual Meeting and ExpositionNovember 4, 2021 9:00 AM Form 8-K bluebird bio, Inc. For: Nov 03November 4, 2021 7:32 AM